Predictive Value of Cytokines and Immune Activation Biomarkers in AIDS-Related Non-Hodgkin Lymphoma Treated with Rituximab plus Infusional EPOCH (AMC-034 trial)

Marta Epeldegui, Jeannette Y. Lee, Anna C. Martínez, Daniel P. Widney, Larry I. Magpantay, Deborah Regidor, Ronald Mitsuyasu, Joseph A. Sparano, Richard F. Ambinder, Otoniel Martínez-Maza

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Purpose: The aims of this study were to determine whether pretreatment plasma levels of cytokines and immune activation- associated molecules changed following treatment for AIDS-NHL with rituximab plus infusional EPOCH, and to determine whether pretreatment levels of these molecules were associated with response to treatment and/or survival. Experimental Design: We quantified plasma levels of B-cell activation-associated molecules (sCD27, sCD30, and sCD23) and cytokines (IL6, IL10, and CXCL13) before and after the initiation of treatment in persons with AIDS-NHL (n = 69) in the AIDS Malignancies Consortium (AMC) 034 study, which evaluated treatment of AIDS-NHL with EPOCH chemotherapy and rituximab. Results: Treatment resulted in decreased plasma levels of some of these molecules (CXCL13, sCD27, and sCD30), with decreased levels persisting for one year following the completion of treatment. Lower levels of CXCL13 before treatment were associated with complete responses following lymphoma therapy. Elevated levels of IL6 pretreatment were associated with decreased overall survival, whereas higher IL10 levels were associated with shorter progression-free survival (PFS), in multivariate analyses. Furthermore, patients with CXCL13 or IL6 levels higher than the median levels for theNHLgroup, as well as those whohad detectable IL10, had lower overall survival and PFS, in Kaplan-Meier analyses. Conclusions: These results indicate that CXCL13, IL6, and IL10 have significant potential as prognostic biomarkers for AIDS-NHL.

Original languageEnglish (US)
Pages (from-to)328-336
Number of pages9
JournalClinical Cancer Research
Volume22
Issue number2
DOIs
StatePublished - Jan 15 2016

Fingerprint

AIDS-Related Lymphoma
Non-Hodgkin's Lymphoma
Acquired Immunodeficiency Syndrome
Biomarkers
Cytokines
Interleukin-10
Interleukin-6
Neoplasms
Therapeutics
Disease-Free Survival
Survival
Rituximab
Kaplan-Meier Estimate
Lymphoma
B-Lymphocytes
Research Design
Multivariate Analysis
Drug Therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Predictive Value of Cytokines and Immune Activation Biomarkers in AIDS-Related Non-Hodgkin Lymphoma Treated with Rituximab plus Infusional EPOCH (AMC-034 trial). / Epeldegui, Marta; Lee, Jeannette Y.; Martínez, Anna C.; Widney, Daniel P.; Magpantay, Larry I.; Regidor, Deborah; Mitsuyasu, Ronald; Sparano, Joseph A.; Ambinder, Richard F.; Martínez-Maza, Otoniel.

In: Clinical Cancer Research, Vol. 22, No. 2, 15.01.2016, p. 328-336.

Research output: Contribution to journalArticle

Epeldegui, M, Lee, JY, Martínez, AC, Widney, DP, Magpantay, LI, Regidor, D, Mitsuyasu, R, Sparano, JA, Ambinder, RF & Martínez-Maza, O 2016, 'Predictive Value of Cytokines and Immune Activation Biomarkers in AIDS-Related Non-Hodgkin Lymphoma Treated with Rituximab plus Infusional EPOCH (AMC-034 trial)', Clinical Cancer Research, vol. 22, no. 2, pp. 328-336. https://doi.org/10.1158/1078-0432.CCR-14-0466
Epeldegui, Marta ; Lee, Jeannette Y. ; Martínez, Anna C. ; Widney, Daniel P. ; Magpantay, Larry I. ; Regidor, Deborah ; Mitsuyasu, Ronald ; Sparano, Joseph A. ; Ambinder, Richard F. ; Martínez-Maza, Otoniel. / Predictive Value of Cytokines and Immune Activation Biomarkers in AIDS-Related Non-Hodgkin Lymphoma Treated with Rituximab plus Infusional EPOCH (AMC-034 trial). In: Clinical Cancer Research. 2016 ; Vol. 22, No. 2. pp. 328-336.
@article{6acc076a96314a489d01a989296ab1a1,
title = "Predictive Value of Cytokines and Immune Activation Biomarkers in AIDS-Related Non-Hodgkin Lymphoma Treated with Rituximab plus Infusional EPOCH (AMC-034 trial)",
abstract = "Purpose: The aims of this study were to determine whether pretreatment plasma levels of cytokines and immune activation- associated molecules changed following treatment for AIDS-NHL with rituximab plus infusional EPOCH, and to determine whether pretreatment levels of these molecules were associated with response to treatment and/or survival. Experimental Design: We quantified plasma levels of B-cell activation-associated molecules (sCD27, sCD30, and sCD23) and cytokines (IL6, IL10, and CXCL13) before and after the initiation of treatment in persons with AIDS-NHL (n = 69) in the AIDS Malignancies Consortium (AMC) 034 study, which evaluated treatment of AIDS-NHL with EPOCH chemotherapy and rituximab. Results: Treatment resulted in decreased plasma levels of some of these molecules (CXCL13, sCD27, and sCD30), with decreased levels persisting for one year following the completion of treatment. Lower levels of CXCL13 before treatment were associated with complete responses following lymphoma therapy. Elevated levels of IL6 pretreatment were associated with decreased overall survival, whereas higher IL10 levels were associated with shorter progression-free survival (PFS), in multivariate analyses. Furthermore, patients with CXCL13 or IL6 levels higher than the median levels for theNHLgroup, as well as those whohad detectable IL10, had lower overall survival and PFS, in Kaplan-Meier analyses. Conclusions: These results indicate that CXCL13, IL6, and IL10 have significant potential as prognostic biomarkers for AIDS-NHL.",
author = "Marta Epeldegui and Lee, {Jeannette Y.} and Mart{\'i}nez, {Anna C.} and Widney, {Daniel P.} and Magpantay, {Larry I.} and Deborah Regidor and Ronald Mitsuyasu and Sparano, {Joseph A.} and Ambinder, {Richard F.} and Otoniel Mart{\'i}nez-Maza",
year = "2016",
month = "1",
day = "15",
doi = "10.1158/1078-0432.CCR-14-0466",
language = "English (US)",
volume = "22",
pages = "328--336",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - Predictive Value of Cytokines and Immune Activation Biomarkers in AIDS-Related Non-Hodgkin Lymphoma Treated with Rituximab plus Infusional EPOCH (AMC-034 trial)

AU - Epeldegui, Marta

AU - Lee, Jeannette Y.

AU - Martínez, Anna C.

AU - Widney, Daniel P.

AU - Magpantay, Larry I.

AU - Regidor, Deborah

AU - Mitsuyasu, Ronald

AU - Sparano, Joseph A.

AU - Ambinder, Richard F.

AU - Martínez-Maza, Otoniel

PY - 2016/1/15

Y1 - 2016/1/15

N2 - Purpose: The aims of this study were to determine whether pretreatment plasma levels of cytokines and immune activation- associated molecules changed following treatment for AIDS-NHL with rituximab plus infusional EPOCH, and to determine whether pretreatment levels of these molecules were associated with response to treatment and/or survival. Experimental Design: We quantified plasma levels of B-cell activation-associated molecules (sCD27, sCD30, and sCD23) and cytokines (IL6, IL10, and CXCL13) before and after the initiation of treatment in persons with AIDS-NHL (n = 69) in the AIDS Malignancies Consortium (AMC) 034 study, which evaluated treatment of AIDS-NHL with EPOCH chemotherapy and rituximab. Results: Treatment resulted in decreased plasma levels of some of these molecules (CXCL13, sCD27, and sCD30), with decreased levels persisting for one year following the completion of treatment. Lower levels of CXCL13 before treatment were associated with complete responses following lymphoma therapy. Elevated levels of IL6 pretreatment were associated with decreased overall survival, whereas higher IL10 levels were associated with shorter progression-free survival (PFS), in multivariate analyses. Furthermore, patients with CXCL13 or IL6 levels higher than the median levels for theNHLgroup, as well as those whohad detectable IL10, had lower overall survival and PFS, in Kaplan-Meier analyses. Conclusions: These results indicate that CXCL13, IL6, and IL10 have significant potential as prognostic biomarkers for AIDS-NHL.

AB - Purpose: The aims of this study were to determine whether pretreatment plasma levels of cytokines and immune activation- associated molecules changed following treatment for AIDS-NHL with rituximab plus infusional EPOCH, and to determine whether pretreatment levels of these molecules were associated with response to treatment and/or survival. Experimental Design: We quantified plasma levels of B-cell activation-associated molecules (sCD27, sCD30, and sCD23) and cytokines (IL6, IL10, and CXCL13) before and after the initiation of treatment in persons with AIDS-NHL (n = 69) in the AIDS Malignancies Consortium (AMC) 034 study, which evaluated treatment of AIDS-NHL with EPOCH chemotherapy and rituximab. Results: Treatment resulted in decreased plasma levels of some of these molecules (CXCL13, sCD27, and sCD30), with decreased levels persisting for one year following the completion of treatment. Lower levels of CXCL13 before treatment were associated with complete responses following lymphoma therapy. Elevated levels of IL6 pretreatment were associated with decreased overall survival, whereas higher IL10 levels were associated with shorter progression-free survival (PFS), in multivariate analyses. Furthermore, patients with CXCL13 or IL6 levels higher than the median levels for theNHLgroup, as well as those whohad detectable IL10, had lower overall survival and PFS, in Kaplan-Meier analyses. Conclusions: These results indicate that CXCL13, IL6, and IL10 have significant potential as prognostic biomarkers for AIDS-NHL.

UR - http://www.scopus.com/inward/record.url?scp=84958968962&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958968962&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-14-0466

DO - 10.1158/1078-0432.CCR-14-0466

M3 - Article

C2 - 26384320

AN - SCOPUS:84958968962

VL - 22

SP - 328

EP - 336

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 2

ER -